PHILADELPHIA-Evidence for the role of diet in the etiology of prostate cancer is mounting and with it, the possibility that nutritional factors can help prevent the disease, Demetrius Albanes, MD, said at the annual meeting of the Society of Nutritional Oncology Adjuvant Therapy. Dr. Albanes is a senior investigator with the Cancer Prevention Studies Branch of the National Cancer Institute.
NEW YORK, New York-Estramustine (Emcyt) can potentiate the effects of taxanes, and the combination might offer a new therapeutic possibility for patients with hormone-resistant prostate cancer. The combination is being tested in clinical trials described by Anne Hamilton, MD, of New York University Medical Center, at a clinical investigators’ workshop sponsored by the University of Texas M. D. Anderson Cancer Center and Pharmacia Oncology.
A potential new treatment under development for prostate cancer may offer clinical advantages, researchers reported at the annual meeting of the American Urological Association in Atlanta.
Recently, there has been much controversy over whether patients with prostate cancer should be treated with bisphosphonates not only to decrease pain, but to prevent metastasis.
Recently, there has been much controversy over whether patients with prostate cancer should be treated with bisphosphonates not only to decrease pain, but to prevent metastasis.
Recently, there has been much controversy over whether patients with prostate cancer should be treated with bisphosphonates not only to decrease pain, but to prevent metastasis.
NEW ORLEANS-In a phase II study, weekly docetaxel (Taxotere) significantly reduced bone pain and PSA levels in men with hormone-refractory prostate cancer, and these results led to enhanced quality of life. Lead investigator Tomasz Beer, MD, of Oregon Health Sciences University, reported the results at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Clinical results demonstrate the potential of an investigational drug, exisulind (Aptosyn), to delay the need for androgen-deprivation therapy in men who have undergone prostatectomy and are at risk of prostate cancer recurrence. Detailed
SAN FRANCISCO-A new study supports the hypothesis that calcium consumption is associated with a greater risk of prostate cancer. June M. Chan, ScD, Department of Epidemiology, Harvard School of Public Health, presented the results at the 91st Annual Meeting of the American Association for Cancer Research (AACR).
NEW YORK-A small trial of trastuzumab (Herceptin) alone and with paclitaxel (Taxol) found that the combination was active against prostate cancer, but trastuzumab alone was not. The results were presented at the ASCO meeting by Michael J. Morris, MD, of Memorial Sloan-Kettering Cancer Center.
PHILADELPHIA-Significant benefit can be achieved from long-term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced prostate cancer.
Five-year follow-up data presented at the annual meeting of the American Urological Association (AUA) in Atlanta showed that the use of cryoablation as first-line treatment for prostate cancer can be as effective as radiation therapy. The five-center,
ATLANTA-For men with advanced or recurrent prostate cancer, 24 months of androgen deprivation accelerates bone loss, and these changes were significant at sites such as the forearm and hip, David M. Preston, MD (Maj., Medical Corps, U.S. Army), reported at the 95th Annual Meeting of the American Urological Association (AUA).
A multi-institutional study demonstrated that prostate cancer patients with aggressive tumors benefited from higher-than-standard doses of radiation. In the trial, 79% of 102 patients receiving radiation therapy for cancer confined to the prostate
TORONTO, Canada-A multicenter phase III trial involving more than 250 prostate cancer patients confirmed earlier trials demonstrating that abarelix, a GnRH antagonist, achieved more rapid reduction of testosterone to castrate levels than leuprolide acetate (Lupron) and bicalutamide (Casodex), but did not produce a testosterone surge and clinical flare.
ST. LOUIS-An automated technique for coregistering MRI or CT images with SPECT (single photo emission computed tomography) images has the potential to improve the accuracy of prostate cancer staging, according to research presented at the Society of Nuclear Medicine 47th Annual Meeting.
Current techniques for permanent prostate brachytherapy are associated with excellent biochemical control in patients with localized prostate cancer. Data now available confirm 5- to 10-year results with this treatment
AstraZeneca has announced the launch of a new website that will help keep researchers and physicians up to date on
Three-dimensional conformal radiation therapy (3D CRT) is more effective yet costs no more than conventional radiation therapy in the long-term treatment of prostate cancer, according to a study conducted at Fox Chase Cancer Center in
Physicians have long known that male hormones fuel prostate cancer growth. That’s why therapies that block the production of androgen-or testosterone-provide some of the most effective therapies for advanced prostate cancer. Certain drugs, for
ATLANTA-Many urologists treating men with prostate cancer are unaware that their patients are experiencing such disturbing treatment side effects as hot flashes, altered bowel habits, or weight change, according to the results of a national survey announced at the 95th Annual Meeting of the American Urological Association (AUA).
The US Food and Drug Administration has approved ALZA Corporation’s new drug application for a
AstraZeneca recently filed a supplemental new drug application with the US Food and Drug Administration (FDA) for a new indication for its oral hormonal medication bicalutamide (Casodex). The supplemental application asks the FDA to approve
FT. LAUDERDALE, Fla-Slight changes in the administration of salvage therapy after radical prostatectomy are among several revisions to the National Comprehensive Cancer Network (NCCN) Practice Guidelines for Prostate Cancer. The revised guidelines recommend radiotherapy for men with positive margins whose prostate-specific antigen (PSA) levels fail to fall to 0 ng/mL after surgery.
The results of an exploratory analysis published in the March 2000 issue of Urology suggest that prolonged combined androgen blockade (CAB) significantly increases survival in patients with advanced prostate cancer.
